Sign inJoin waitlistJoin the waitlist

Craig Lockhart

Division Chief, Division of Hematology and Oncology · Medical University of South Carolina College of Medicine

Credentials: · · · · · · ·

History

Division of Hematology and Oncology · Medical University of South Carolina College of Medicine
Present
Division of Hematology & Oncology · Medical University of South Carolina College of Medicine
Present
APP Fellowship - Hematology-Oncology · Medical University of South Carolina College of Medicine
Present

Hematology and Medical Oncology
Washington University School of Medicine
2002–2005
Hematology and Medical Oncology
Duke University Hospital
1999–2002
Center
1996–1999
Internal Medicine
Barnes-Jewish Hospital
1993–1996
Vanderbilt University
Univ of Texas Southwestern Med Sch at Dallas
1989–1993
University
1985–1989

Research

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2016 · 750 citations
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a…
The Lancet Oncology · 2016 · 679 citations
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Nature · 2018 · 645 citations

Andrea Wang-Gillam
23 papers
BT
Benjamin Tan
16 papers
Jordan Berlin
16 papers
Mace Rothenberg
16 papers
RS
Rama Suresh
13 papers
JP
Joel Picus
11 papers
KL
Kian-Huat Lim
9 papers
Nipun Merchant
9 papers
John Sarantopoulos
8 papers
Mary Washington
8 papers
WK
Wolfgang Korn
8 papers
Manik Amin
7 papers · 2 as a fellow

Grants

Medical University of South Carolina NCORP Community Site
National Cancer Institute · UG1
PI · $5.9M · Medical University of South Carolina
2014–2027
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program
National Cancer Institute · K12
PI · $1M · Medical University of South Carolina
2013–2024
Washington University SPORE in Pancreatic Cancer
National Cancer Institute · P50
Project lead · $463.3K · Washington University
2016–2022
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Cancer Institute · UM1
PI · $707.3K · Duke University
2014–2019

Clinical trials

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Principal investigator · Recruiting · Phase 2
Medical University of South Carolina
2026–2029
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Principal investigator · Completed · Phase 2
Vanderbilt University
2007–2013
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2028
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Site PI · Recruiting
NRG Oncology
2022–2065